|
This information is provided for educational purposes only. Reader retains full responsibility for the use of the information contained herein.
For the past 35 years, DrugPak has been a trailblazer in the drug testing industry. From introducing cutting-edge technology to developing solutions that set the standard for accuracy and efficiency, DrugPak has always been at the forefront of innovation. And as we celebrate three decades of excellence, we are more committed than ever to shaping the future of drug testing. A Legacy of Innovation Since our inception, DrugPak has been driven by one mission: to make drug testing more reliable, accessible, and user-friendly. Over the years, we've consistently raised the bar with products designed to meet the evolving needs of the industry. Whether it’s enhancing the accuracy of test results or streamlining the testing process, we've always focused on pushing the limits of what's possible Our commitment to innovation is not just about staying ahead of the curve--it’s about setting new standards that others can follow. The technology we’ve introduced over the past 35 years has not only transformed how drug testing is performed but has also improved the accuracy and efficiency of results, ultimately helping to keep workplaces and communities safer. Two of our major innovations were brought to market back in 2000 and 2001. We were the first to offer encrypted email. At this point drug testing results had been being emailed for a few years. We recognized the potential risk associated with the sensitive information that drug test results contained being sent without security measures. In the following year, 2001, we offered our clients the ability to securely self-host their own web portal. These two offerings helped set a bar of security and software flexibility for not only our customers but the industry. The Future of Drug Testing While we’re proud of the advancements we’ve made so far, we know that the future of drug testing holds even greater potential. As new challenges arise, so do new opportunities for innovation. At DrugPak, we’re already looking ahead to what’s next. From the rise of non-invasive testing methods to the integration of artificial intelligence and machine learning, we’re exploring cutting-edge technologies that will make drug testing faster, more efficient, and more cost-effective than ever before. Since 2018, DrugPak has been using AI to accelerate the drug testing process. Some of the ways this is done include handling of documents and document identification. DrugPak’s web software is able to read the Department of Transportation (DOT) flags for substance type, identify if signatures are present and match documents with data to expedite the overall drug testing process. But we’re not just investing in technology--we’re also investing in the people behind the technology. Our team is continuously growing, with experts in science, engineering, and data analytics all working together to bring the industry the best solutions. We believe that by combining human expertise with advanced technology, we can continue to lead the way in drug testing for years to come. Continuing the Legacy For 35 years, DrugPak has been proud to serve clients across a wide range of industries, from healthcare and education to transportation and corporate settings. As we look to the future, we’re excited to continue building on the legacy we’ve established and remain a valued and trusted partner in drug testing. The journey doesn’t end here--there’s so much more to come. Our commitment to providing innovative, reliable, and accurate drug testing solutions is stronger than ever. We’re ready to continue leading the way, and we invite you to join us as we shape the next era of drug testing. Visit our website to learn more: drugpak.com © 2010-2025 DrugPak – No portion of this article may be reproduced, retransmitted, posted on a website, or used in any manner without the written consent of the DrugPak. When permission is granted to reproduce this article in any way, full attribution to the author and copyright holder is required. Comments are closed.
|
RSS Feed
|
|